kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine

TS Shippenberg, A LeFevour and C Heidbreder

Behavioral Pharmacology and Genetics Section, NIDA Intramural Research Program, Baltimore, Maryland, USA.

A place preference conditioning procedure was used to examine the influence of kappa-opioid receptor ligands upon the development of sensitization to the conditioned rewarding effects of cocaine. Previous exposure to cocaine (10-20 mg/kg; i.p.; days 1-5) resulted in an enhancement of the conditioned rewarding effects of this agent, e.g., sensitization. Thus, doses of cocaine (5.0-10.0 mg/kg; i.p.) that failed to produce place preferences in control rats produced significant place preferences in cocaine-experienced animals. In animals that had received the kappa-agonist U50,488H (5.0 mg/kg; s.c.) in combination with the repeated cocaine treatment regimen, no enhancement of cocaine-induced place conditioning was seen. Similarly, the kappa-agonist U69593 administered on days 1 to 5 or only on days 3 to 5 of the cocaine treatment regimen prevented the enhanced response to cocaine. This effect occurred after either systemic (0.04-0.16 mg/kg; s.c.) or intracerebroventricular (1.0 mg) treatment and was abolished by the kappa-opioid receptor antagonist, nor-binaltorphimine. In contrast to its effects when administered in combination with cocaine, prior administration of U69593, alone, failed to modify the conditioned response to cocaine. Microdialysis studies revealed a marked elevation of extracellular dopamine levels within the ventral striatum after repeated cocaine administration. In animals that had received U69593 in combination with cocaine, no elevation of dopamine was seen. These data demonstrate that sensitization develops to the conditioned rewarding effects of cocaine and that the activation of central nervous system kappa-opioid receptors prevents the development of this phenomenon. An involvement of the mesolimbic dopamine system in mediating the interaction of kappa-agonists with cocaine is suggested.

Volume 276, Issue 2, pp. 545-554, 02/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				W. S. Sheng, S. Hu, G. Herr, H. T. Ni, R. B. Rock, G. Gekker, J. R. Lokensgard, and P. K. Peterson Human Neural Precursor Cells Express Functional {kappa}-Opioid Receptors J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 957 - 963. [Abstract] [Full Text] [PDF]

				J. L. Mathews, X. Peng, W. Xiong, A. Zhang, S. S. Negus, J. L. Neumeyer, and J. M. Bidlack Characterization of a Novel Bivalent Morphinan Possessing {kappa} Agonist and {micro} Agonist/Antagonist Properties J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 821 - 827. [Abstract] [Full Text] [PDF]

				J. M. Bidlack, D. J. Cohen, J. P. McLaughlin, R. Lou, Y. Ye, and M. P. Wentland 8-Carboxamidocyclazocine: A Long-Acting, Novel Benzomorphan J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 374 - 380. [Abstract] [Full Text] [PDF]

				K. P. Cosgrove and M. E. Carroll Effects of Bremazocine on Self-Administration of Smoked Cocaine Base and Orally Delivered Ethanol, Phencyclidine, Saccharin, and Food in Rhesus Monkeys: A Behavioral Economic Analysis J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 993 - 1002. [Abstract] [Full Text] [PDF]

				S. L. Walsh, B. Geter-Douglas, E. C. Strain, and G. E. Bigelow Enadoline and Butorphanol: Evaluation of kappa -Agonists on Cocaine Pharmacodynamics and Cocaine Self-Administration in Humans J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 147 - 158. [Abstract] [Full Text] [PDF]

				A. C. Thompson, A. Zapata, J. B. Justice Jr, R. A. Vaughan, L. G. Sharpe, and T. S. Shippenberg {kappa}-Opioid Receptor Activation Modifies Dopamine Uptake in the Nucleus Accumbens and Opposes the Effects of Cocaine J. Neurosci., December 15, 2000; 20(24): 9333 - 9340. [Abstract] [Full Text] [PDF]

				F. C. Dalman and K. L. O'Malley kappa -Opioid Tolerance and Dependence in Cultures of Dopaminergic Midbrain Neurons J. Neurosci., July 15, 1999; 19(14): 5750 - 5757. [Abstract] [Full Text] [PDF]

				J. M. van Ree, M. A. F. M. Gerrits, and L. J. M. J. Vanderschuren Opioids, Reward and Addiction: An Encounter of Biology, Psychology, and Medicine Pharmacol. Rev., June 1, 1999; 51(2): 341 - 396. [Abstract] [Full Text] [PDF]

				A. L. Svingos, E. E. O. Colago, and V. M. Pickel Cellular Sites for Dynorphin Activation of kappa -Opioid Receptors in the Rat Nucleus Accumbens Shell J. Neurosci., March 1, 1999; 19(5): 1804 - 1813. [Abstract] [Full Text] [PDF]

				N. K. Mello and S. S. Negus Effects of Kappa Opioid Agonists on Cocaine- and Food-Maintained Responding by Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 812 - 824. [Abstract] [Full Text]

				T. J. Phillips, M. G. Huson, and C. S. McKinnon Localization of Genes Mediating Acute and Sensitized Locomotor Responses to Cocaine in BXD/Ty Recombinant Inbred Mice J. Neurosci., April 15, 1998; 18(8): 3023 - 3034. [Abstract] [Full Text] [PDF]

				J. K. Staley, R. B. Rothman, K. C. Rice, J. Partilla, and D. C. Mash kappa 2 Opioid Receptors in Limbic Areas of the Human Brain Are Upregulated by Cocaine in Fatal Overdose Victims J. Neurosci., November 1, 1997; 17(21): 8225 - 8233. [Abstract] [Full Text] [PDF]

				G. F. Koob and M. L. Moal Drug Abuse: Hedonic Homeostatic Dysregulation Science, October 3, 1997; 278(5335): 52 - 58. [Abstract] [Full Text]

				J. Yu, E. R. Butelman, J. H. Woods, B. T. Chait, and M. J. Kreek Dynorphin A (1-8) Analog, E-2078, Crosses the Blood-Brain Barrier in Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 633 - 638. [Abstract] [Full Text]

				S. S. Negus, N. K. Mello, P. S. Portoghese, and C.-E. Lin Effects of Kappa Opioids on Cocaine Self-Administration by Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 44 - 55. [Abstract] [Full Text]